Milena Barcza Stockler-Pinto

Dr. Milena Barcza Stockler-Pinto


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2013 in Biochimie
Verified
Journal Article
Closed access
LCLudmila Cardozo
Ludmila Cardozo
LPLiliana M. Pedruzzi
Liliana M. Pedruzzi
PSPeter Stenvinkel
Peter Stenvinkel
MSMilena Barcza Stockler-Pinto
Milena Barcza Stockler-Pinto
JDJulio Daleprane
Julio Daleprane
Denise MafraDenise Mafra
Denise Mafra

1 December 2012 in Biochimie
Verified
Journal Article
Closed access
LPLiliana Magnago Pedruzzi
Liliana Magnago Pedruzzi
MSMilena Barcza Stockler-Pinto
Milena Barcza Stockler-Pinto
MLMaurilo Leite
Maurilo Leite
Denise MafraDenise Mafra
Denise Mafra

1 January 2018 in Journal of Renal Nutrition
Verified
Journal Article
Closed access
NBNatália Alvarenga Borges
Natália Alvarenga Borges
FCFlávia L. Carmo
Flávia L. Carmo
MSMilena Barcza Stockler-Pinto
Milena Barcza Stockler-Pinto
JBJessyca S. de Brito
Jessyca S. de Brito
CDCarla J. Dolenga
Carla J. Dolenga
Denise MafraDenise Mafra
Denise Mafra

16 November 2018 in Food & Function
Verified
Journal Article
Closed access
PDF file
MEMarta Esgalhado
Marta Esgalhado
Julie Ann KempJulie Ann Kemp
Julie Ann Kemp
RARenata Azevedo
Renata Azevedo
BPBruna R. Paiva
Bruna R. Paiva
MSMilena Barcza Stockler-Pinto
Milena Barcza Stockler-Pinto
Denise MafraDenise Mafra
Denise Mafra
An imbalance of gut microbiota is considered a new cardiovascular risk factor for chronic kidney disease (CKD) patients, since it is directly associated with increased uremic toxin production, inflammation and oxidative stress. Strategies such as prebiotic supplementation have been suggested to mitigate these complications. We hypothesized that prebiotic-resistant starch could ameliorate uremic toxins levels, oxidative stress, and inflammatory states in hemodialysis (HD) patients. This pilot study evaluated 31 HD patients assigned to either resistant starch (16 g of resistant starch Hi-Maize® 260) or placebo (manioc flour) supplementation, which they received for 4 weeks on alternate days through cookies on dialysis days and powder in a sachet on non-dialysis days. Levels of interleukin (IL)-6, high-sensitive C-reactive protein, thiobarbituric acid reactive substances plasma (TBARS), protein carbonylation, indoxyl sulfate (IS) and p-cresyl sulfate were measured. Anthropometric and biochemical parameters, as well as, food intake were also evaluated. As expected, resistant starch group increased fiber intake (p > 0.01), in addition the prebiotic supplementation reduced IL-6 (p = 0.01), TBARS (p > 0.01), and IS (p > 0.01) plasma levels. No significant differences were evident in the placebo group. Prebiotic-resistant starch supplementation seems to be a promising nutritional strategy to improve inflammation, oxidative stress and to reduce IS plasma levels in CKD patients on HD.

3 February 2021 in European Journal of Nutrition
Verified
Journal Article
Closed access
PDF file
DCDr. Coutinho-Wolino
Dr. Coutinho-Wolino
LCLudmila Cardozo
Ludmila Cardozo
VLViviane de Oliveira Leal
Viviane de Oliveira Leal
Denise MafraDenise Mafra
Denise Mafra
MSMilena Barcza Stockler-Pinto
Milena Barcza Stockler-Pinto

14 January 2015 in Journal Of Nephrology
Verified
Journal Article
Closed access
PDF file
LPLiliana M. Pedruzzi
Liliana M. Pedruzzi
LCLudmila Cardozo
Ludmila Cardozo
JDJulio Daleprane
Julio Daleprane
MSMilena Barcza Stockler-Pinto
Milena Barcza Stockler-Pinto
EMElisa B. Monteiro
Elisa B. Monteiro
Denise MafraDenise Mafra
Denise Mafra
Oxidative stress and inflammation are common features and the main mediators of progression of chronic kidney disease (CKD) and its cardiovascular complications. Under normal conditions, oxidative stress activates the transcription factor, nuclear factor E2-related factor 2 (Nrf2), which is the master regulator of genes encoding antioxidant and detoxifying enzymes and related proteins. The available data on expression of Nrf2 and its key target gene products in CKD patients is limited. We therefore investigated this topic in a group of CKD patients on hemodialysis.